Compare Stocks: ACHV, ATAI, RGC, and TRVI

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACHV Achieve Life Sciences	$6.91 +3.5%	$5.96	$2.37 ▼ $7.11	$708.87M	2.24	1.30 million shs	1.08 million shs
ATAI Atai Beckley	$7.25 -0.1%	$5.53	$3.27 ▼ $7.26	$2.67B	1.54	7.85 million shs	1.64 million shs
RGC Regencell Bioscience	$5.17 -2.0%	$9.75	$4.51 ▼ $69.00	$2.56B	1.88	313,905 shs	54,868 shs
TRVI Trevi Therapeutics	$17.60 -1.1%	$17.05	$6.93 ▼ $20.22	$2.51B	1.03	1.73 million shs	565,426 shs

10 Best Stocks to Own - Summer 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACHV Achieve Life Sciences	+0.30%	+5.54%	+9.17%	+11.35%	+166.80%
ATAI Atai Beckley	0.00%	+0.97%	+40.23%	+74.70%	+75.54%
RGC Regencell Bioscience	-2.40%	-13.87%	-10.20%	-79.96%	-62.20%
TRVI Trevi Therapeutics	-3.84%	-0.56%	-0.22%	+20.60%	+139.89%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACHV Achieve Life Sciences	$6.91 +3.5%	$5.96	$2.37 ▼ $7.11	$708.87M	2.24	1.30 million shs	1.08 million shs
ATAI Atai Beckley	$7.25 -0.1%	$5.53	$3.27 ▼ $7.26	$2.67B	1.54	7.85 million shs	1.64 million shs
RGC Regencell Bioscience	$5.17 -2.0%	$9.75	$4.51 ▼ $69.00	$2.56B	1.88	313,905 shs	54,868 shs
TRVI Trevi Therapeutics	$17.60 -1.1%	$17.05	$6.93 ▼ $20.22	$2.51B	1.03	1.73 million shs	565,426 shs

10 Best Stocks to Own - Summer 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACHV Achieve Life Sciences	+0.30%	+5.54%	+9.17%	+11.35%	+166.80%
ATAI Atai Beckley	0.00%	+0.97%	+40.23%	+74.70%	+75.54%
RGC Regencell Bioscience	-2.40%	-13.87%	-10.20%	-79.96%	-62.20%
TRVI Trevi Therapeutics	-3.84%	-0.56%	-0.22%	+20.60%	+139.89%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACHV Achieve Life Sciences	3.00	Buy	$16.00	131.72% Upside
ATAI Atai Beckley	2.27	Hold	$11.06	52.61% Upside
RGC Regencell Bioscience	1.00	Sell	N/A	N/A
TRVI Trevi Therapeutics	3.00	Buy	$26.75	51.96% Upside

Current Analyst Ratings Breakdown

Latest ACHV, ATAI, RGC, and TRVI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/7/2026	TRVI Trevi Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$23.00
8/7/2026	TRVI Trevi Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$24.00 ➝ $25.00
8/7/2026	TRVI Trevi Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Strong-Buy	$40.00
8/7/2026	TRVI Trevi Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$25.00 ➝ $30.00
7/20/2026	TRVI Trevi Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$36.00
7/20/2026	ATAI Atai Beckley	Berenberg Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$7.45
7/20/2026	ATAI Atai Beckley	Berenberg Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/20/2026	ATAI Atai Beckley	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$25.00 ➝ $7.50
7/20/2026	TRVI Trevi Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
7/20/2026	TRVI Trevi Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$21.00 ➝ $31.00
7/20/2026	TRVI Trevi Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$21.00 ➝ $24.00

(Data available from 8/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACHV Achieve Life Sciences	N/A	N/A	N/A	N/A	$0.40 per share	N/A
ATAI Atai Beckley	$4.09M	652.17	N/A	N/A	$0.69 per share	10.50
RGC Regencell Bioscience	N/A	N/A	N/A	N/A	$0.01 per share	N/A
TRVI Trevi Therapeutics	N/A	N/A	N/A	N/A	$1.43 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACHV Achieve Life Sciences	-$54.65M	-$1.12	N/A	N/A	N/A	N/A	-193.49%	-111.88%	N/A
ATAI Atai Beckley	-$660.05M	-$2.23	N/A	N/A	N/A	-19,019.44%	-89.79%	-63.58%	8/13/2026 (Estimated)
RGC Regencell Bioscience	-$3.58M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TRVI Trevi Therapeutics	-$42.76M	-$0.34	N/A	N/A	N/A	N/A	-23.59%	-22.64%	N/A

Latest ACHV, ATAI, RGC, and TRVI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	ATAI Atai Beckley	-$0.1088	N/A	N/A	N/A	$0.11 million	N/A
8/11/2026	Q2 2026	ACHV Achieve Life Sciences	-$0.1649	-$0.28	-$0.1151	-$0.80	N/A	N/A
8/6/2026	Q2 2026	TRVI Trevi Therapeutics	-$0.1095	-$0.11	-$0.0005	-$0.11	N/A	N/A
5/12/2026	Q1 2026	ACHV Achieve Life Sciences	-$0.30	-$0.19	+$0.11	-$0.19	N/A	N/A
5/12/2026	Q4 2025	ATAI Atai Beckley	-$0.11	-$0.08	+$0.03	-$0.08	$0.22 million	$0.95 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACHV Achieve Life Sciences	N/A	N/A	N/A	N/A	N/A
ATAI Atai Beckley	N/A	N/A	N/A	N/A	N/A
RGC Regencell Bioscience	N/A	N/A	N/A	N/A	N/A
TRVI Trevi Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACHV Achieve Life Sciences	0.87	2.62	2.62
ATAI Atai Beckley	N/A	N/A	N/A
RGC Regencell Bioscience	N/A	1.41	N/A
TRVI Trevi Therapeutics	N/A	37.28	37.28

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACHV Achieve Life Sciences	33.52%
ATAI Atai Beckley	28.41%
RGC Regencell Bioscience	0.13%
TRVI Trevi Therapeutics	95.76%

Insider Ownership

Company	Insider Ownership
ACHV Achieve Life Sciences	1.80%
ATAI Atai Beckley	19.80%
RGC Regencell Bioscience	N/A
TRVI Trevi Therapeutics	15.39%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACHV Achieve Life Sciences	20	102.66 million	100.81 million	Optionable
ATAI Atai Beckley	80	368.17 million	295.27 million	Optionable
RGC Regencell Bioscience	10	494.49 million	N/A	N/A
TRVI Trevi Therapeutics	20	142.48 million	120.55 million	Optionable

ACHV, ATAI, RGC, and TRVI Headlines

Recent News About These Companies

1,525,314 Shares in Trevi Therapeutics, Inc. $TRVI Acquired by Assenagon Asset Management S.A.

August 10 at 3:11 AM | marketbeat.com

Trevi Therapeutics (NASDAQ:TRVI) Price Target Raised to $30.00

August 10 at 2:12 AM | americanbankingnews.com

Trevi Therapeutics (NASDAQ:TRVI) Announces Earnings Results, Hits Estimates

August 7, 2026 | marketbeat.com

Trevi Therapeutics Q2 Earnings Call Highlights

August 7, 2026 | marketbeat.com

Cantor Fitzgerald Forecasts Strong Price Appreciation for Trevi Therapeutics (NASDAQ:TRVI) Stock

August 7, 2026 | marketbeat.com

Trevi Therapeutics, Inc. (TRVI) Q2 2026 Earnings Call Transcript

August 6, 2026 | seekingalpha.com

Trevi Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

August 6, 2026 | globenewswire.com

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Average Recommendation of "Buy" by Brokerages

August 5, 2026 | americanbankingnews.com

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Average Rating of "Buy" from Analysts

July 31, 2026 | marketbeat.com

Trevi Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026

July 30, 2026 | globenewswire.com

Trevi Therapeutics (TRVI) to Post Earnings on Thursday

July 30, 2026 | marketbeat.com

Trevi Therapeutics to Participate in Upcoming August Conferences

July 28, 2026 | globenewswire.com

Trevi Therapeutics, Inc. $TRVI Shares Sold by Orbimed Advisors LLC

July 27, 2026 | marketbeat.com

Octagon Capital Advisors LP Reduces Stock Holdings in Trevi Therapeutics, Inc. $TRVI

July 27, 2026 | marketbeat.com

Affinity Asset Advisors LLC Sells 150,000 Shares of Trevi Therapeutics, Inc. $TRVI

July 25, 2026 | marketbeat.com

Trevi Therapeutics (NASDAQ:TRVI) Downgraded by Wall Street Zen to "Sell"

July 25, 2026 | marketbeat.com

Siren L.L.C. Cuts Holdings in Trevi Therapeutics, Inc. $TRVI

July 24, 2026 | marketbeat.com

Fifth Third Bancorp Invests $1.53 Million in Trevi Therapeutics, Inc. $TRVI

July 24, 2026 | marketbeat.com

Trevi Therapeutics (NASDAQ:TRVI) Rating Increased to Strong-Buy at BMO Capital Markets

July 22, 2026 | marketbeat.com

Trevi Therapeutics (NASDAQ:TRVI) Shares Down 5.1% - Here's Why

July 20, 2026 | marketbeat.com

B. Riley Financial Issues Positive Forecast for Trevi Therapeutics (NASDAQ:TRVI) Stock Price

July 20, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACHV, ATAI, RGC, and TRVI Company Descriptions

Achieve Life Sciences NASDAQ:ACHV

$6.90 +0.24 (+3.52%)

As of 01:31 PM Eastern

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc. is based in Vancouver, Canada.

Atai Beckley NASDAQ:ATAI

$7.24 -0.01 (-0.07%)

As of 01:31 PM Eastern

Atai Beckley N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. Atai Beckley N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

Regencell Bioscience NASDAQ:RGC

$5.17 -0.11 (-2.01%)

As of 01:31 PM Eastern

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.

Trevi Therapeutics NASDAQ:TRVI

$17.60 -0.20 (-1.11%)

As of 01:31 PM Eastern

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ACHV, ATAI, RGC, and TRVI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ACHV, ATAI, RGC, and TRVI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ACHV, ATAI, RGC, and TRVI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACHV, ATAI, RGC, and TRVI Company Descriptions

Achieve Life Sciences NASDAQ:ACHV

Atai Beckley NASDAQ:ATAI

Regencell Bioscience NASDAQ:RGC

Trevi Therapeutics NASDAQ:TRVI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ACHV, ATAI, RGC, and TRVI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ACHV, ATAI, RGC, and TRVI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ACHV, ATAI, RGC, and TRVI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACHV, ATAI, RGC, and TRVI Company Descriptions

Achieve Life Sciences NASDAQ:ACHV

Atai Beckley NASDAQ:ATAI

Regencell Bioscience NASDAQ:RGC

Trevi Therapeutics NASDAQ:TRVI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools